Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in LDL-cholesterol when added to standard therapy, as it tries to narrow a lead ...

On December 11, 2025- Kowa Company, Ltd. initiated a phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With ...

Alexion, AstraZeneca (AZN) Rare Disease’s Koselugo, an oral, selective MEK inhibitor, has been approved in the European Union, EU, for the treatment of symptomatic, inoperable plexiform neurofibromas ...